Osteoporosis in the Elderly

• MacLean C , NewberryS, MaglioneMet al.: Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann. Intern. Med.148, 197–213(2008).
   PubMed Web of Science ®Google Scholar
• Green AD , Colon-EmericCS, BastianL, DrakeMT, LylesKW: Does this woman have osteoporosis?JAMA292, 2890–2900(2004).
   PubMed Web of Science ®Google Scholar
• Keen RW : Burden of osteoporosis and fractures.Curr. Osteoporos. Rep.1, 66–70(2003).
   PubMedGoogle Scholar
• Wei GS , JacksonJL, HatzigeorgiouC, TofferiJK: Osteoporosis management in the new millennium.Prim. Care30, 711–741, (2003).
   PubMed Web of Science ®Google Scholar
• Mauck KF , ClarkeBL: Diagnosis, screening, prevention, and treatment of osteoporosis.Mayo Clin. Proc.81, 662–672(2006).
   PubMed Web of Science ®Google Scholar
• Poole KE , CompstonJE: Osteoporosis and its management.Br. Med. J.333, 1251–126(2006).
   PubMed Web of Science ®Google Scholar
• Rosen CJ : Clinical practice. Postmenopausal osteoporosis.N. Engl. J. Med.353, 595–603(2005).
   PubMed Web of Science ®Google Scholar
• Riggs BL , MeltonLJ 3rd: Involutional osteoporosis. N. Engl. J. Med.314, 1676–1686(1986).
   PubMed Web of Science ®Google Scholar
• De Smet AA , RobinsonRG, JohnsonBE, LukertBP: Spinal compression fractures in osteoporotic women: patterns and relationship to hyperkyphosis.Radiology166, 497–500(1988).
   PubMed Web of Science ®Google Scholar
• Raisz LG : Clinical practice. Screening for osteoporosis.N. Engl. J. Med.353, 164–171(2005).
   PubMed Web of Science ®Google Scholar
• Jarvinen TL , SievanenH, KhanKM, HeinonenA, KannusP: Shifting the focus in fracture prevention from osteoporosis to falls.Br. Med. J.336, 124–126(2008).
   PubMed Web of Science ®Google Scholar
• Baim S , BinkleyN, BilezikianJPet al.: Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD position development conference. J. Clin. Densitom.11, 75–91(2008).
   PubMed Web of Science ®Google Scholar
• Kanis JA , JohnellO, De Laet C et al.: A meta-analysis of previous fracture and subsequent fracture risk. Bone35, 375–382(2004).
   PubMed Web of Science ®Google Scholar
• Bolotin HH , SievanenH, GrashuisJL: Patient-specific DXA bone mineral density inaccuracies: quantitative effects of nonuniform extraosseous fat distributions.J. Bone Miner. Res.18, 1020–1027(2003).
   PubMed Web of Science ®Google Scholar
• Cherney DD , LaymonMS, McNittA, Yuly S:A study on the influence of calcified intervertebral disk and aorta in determining bone mineral density. J. Clin. Densitom.5, 193–198(2002).
   PubMed Web of Science ®Google Scholar
• Moro Alvarez MJ , Diaz-CurielM: Pharmacological treatment of osteoporosis for people over 70.Aging Clin. Exp. Res.19, 246–254(2007).
   PubMed Web of Science ®Google Scholar
• Bagger YZ , TankoLB, AlexandersenP, Qin G, Christiansen C: Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J. Intern. Med.259, 598–605(2006).
   PubMed Web of Science ®Google Scholar
• Picard D , BrownJP, RosenthallLet al.: Ability of peripheral DXA measurement to diagnose osteoporosis as assessed by central DXA measurement. J. Clin. Densitom.7, 111–118(2004).
   PubMed Web of Science ®Google Scholar
• Kiel DP , DemissieS, DupuisJ, LunettaKL, MurabitoJM, KarasikD: Genome-wide association with bone mass and geometry in the Framingham Heart Study.BMC Med. Genet.8(Suppl. 1), S14 (2007).
   PubMed Web of Science ®Google Scholar
• Styrkarsdottir U , HalldorssonBV, GretarsdottirSet al.: Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. (2008).
   PubMed Web of Science ®Google Scholar
• Richards JB , RivadeneiraF, InouyeMet al.: Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet371, 1505–1512(2008).
   PubMed Web of Science ®Google Scholar
• Law MR , HackshawAK: A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect.Br. Med. J.315, 841–846(1997).
   PubMed Web of Science ®Google Scholar
• Hourigan SR , NitzJC, BrauerSG, O‘Neill S, Wong J, Richardson CA: Positive effects of exercise on falls and fracture risk in osteopenic women. Osteoporos. Int.19(7), 1077–1086(2008).
   Google Scholar
• Li F , HarmerP, FisherKJet al.: Tai Chi and fall reductions in older adults: a randomized controlled trial. J. Gerontol. A. Biol. Sci. Med. Sci.60, 187–194(2005).
   PubMed Web of Science ®Google Scholar
• Voukelatos A , CummingRG, LordSR, Rissel C:A randomized controlled trial of tai chi for the prevention of falls: the Central Sydney tai chi trial. J. Am. Geriatr. Soc.55, 1185–1191(2007).
   PubMed Web of Science ®Google Scholar
• Villar MT , HillP, InskipH, ThompsonP, CooperC: Will elderly rest home residents wear hip protectors?Age Ageing27, 195–198(1998).
   PubMed Web of Science ®Google Scholar
• Sinaki M : Falls, fractures, and hip pads.Curr. Osteoporos. Rep.2, 131–137(2004).
   PubMedGoogle Scholar
• Jackson RD , LaCroixAZ, GassMet al.: Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med.354, 669–683(2006).
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA , WillettWC, WongJB, GiovannucciE, DietrichT, Dawson-Hughes B: Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA293, 2257–2264(2005).
   PubMed Web of Science ®Google Scholar
• Reginster J , MinneHW, SorensenOHet al.: Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group. Osteoporos. Int.11, 83–91(2000).
   PubMed Web of Science ®Google Scholar
• Solomon CG : Bisphosphonates and osteoporosis.N. Engl. J. Med.346, 642 (2002).
   PubMed Web of Science ®Google Scholar
• Quandt SA , ThompsonDE, SchneiderDL, NevittMC, BlackDM: Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of -1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.Mayo Clin. Proc.80, 343–349(2005).
   PubMed Web of Science ®Google Scholar
• Black DM , ThompsonDE, BauerDCet al.: Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab.85, 4118–4124(2000).
   PubMed Web of Science ®Google Scholar
• Orwoll E , EttingerM, WeissSet al.: Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med.343, 604–610(2000).
   PubMed Web of Science ®Google Scholar
• Black DM , SchwartzAV, EnsrudKEet al.: Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA296, 2927–2938(2006).
   PubMed Web of Science ®Google Scholar
• Sorensen OH , CrawfordGM, MulderHet al.: Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone32, 120–126(2003).
   PubMed Web of Science ®Google Scholar
• McClung MR , GeusensP, MillerPDet al.: Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med.344, 333–340(2001).
   PubMed Web of Science ®Google Scholar
• Harris ST , WattsNB, GenantHKet al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) study group. JAMA282, 1344–1352(1999).
   PubMed Web of Science ®Google Scholar
• Kanis JA , BartonIP, JohnellO: Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.Osteoporos. Int.16, 475–482(2005).
   PubMed Web of Science ®Google Scholar
• Geusens PP , RouxCH, ReidDMet al.: Drug Insight: choosing a drug treatment strategy for women with osteoporosis – an evidence-based clinical perspective. Nat. Clin. Pract. Rheumatol.4, 240–248(2008).
   PubMedGoogle Scholar
• Ebeling PR : Clinical practice. Osteoporosis in men.N. Engl. J. Med.358, 1474–1482(2008).
   PubMed Web of Science ®Google Scholar
• Sebba AI , BonnickSL, KaganRet al.: Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr. Med. Res. Opin.20, 2031–41(2004).
   PubMed Web of Science ®Google Scholar
• Rosen CJ , HochbergMC, BonnickSLet al.: Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res.20, 141–151(2005).
   PubMed Web of Science ®Google Scholar
• Chesnut IC , SkagA, ChristiansenCet al.: Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res.19, 1241–1249(2004).
   PubMed Web of Science ®Google Scholar
• Harris ST , BlumentalsWA, MillerPD: Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of Phase III studies.Curr. Med. Res. Opin.24, 237–245(2008).
   PubMed Web of Science ®Google Scholar
• Black DM , DelmasPD, EastellRet al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356, 1809–1822(2007).
   PubMed Web of Science ®Google Scholar
• Lyles KW , CS Colon-Emeric, Magaziner JS et al.: Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N. Engl. J. Med.357, nihpa40967 (2007).
   Web of Science ®Google Scholar
• Chapurlat RD , PalermoL, RamsayP, CummingsSR: Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.Osteoporos. Int.16, 842–848(2005).
   PubMed Web of Science ®Google Scholar
• Cummings SR , KarpfDB, HarrisFet al.: Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med.112, 281–289(2002).
   PubMed Web of Science ®Google Scholar
• Hochberg MC , GreenspanS, WasnichRD, MillerP, ThompsonDE, RossPD: Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.J. Clin. Endocrinol. Metab.87, 1586–1592(2002).
   PubMed Web of Science ®Google Scholar
• Woo SB , HellsteinJW, KalmarJR: Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws.Ann. Intern. Med.144, 753–761(2006).
   PubMed Web of Science ®Google Scholar
• Migliorati CA , CasigliaJ, EpsteinJ, JacobsenPL, SiegelMA, WooSB: Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper.J. Am. Dent. Assoc.136, 1658–1668(2005).
   PubMed Web of Science ®Google Scholar
• Riggs BL , HartmannLC: Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice.N. Engl. J. Med.348, 618–629(2003).
   PubMed Web of Science ®Google Scholar
• Ettinger B , BlackDM, MitlakBHet al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA282, 637–645(1999).
   PubMed Web of Science ®Google Scholar
• Chesnut CH , 3rd, Silverman S, Andriano K et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am. J. Med.109, 267–276(2000).
   PubMed Web of Science ®Google Scholar
• Cranney A , TugwellP, ZytarukNet al.: Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocr. Rev.23, 540–551(2002).
   PubMed Web of Science ®Google Scholar
• Balasch J : Sex steroids and bone: current perspectives.Hum. Reprod. Update9, 207–222(2003).
   Google Scholar
• Cauley JA , RobbinsJ, ChenZet al.: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women‘s Health Initiative randomized trial. JAMA290, 1729–1738(2003).
   PubMed Web of Science ®Google Scholar
• Wells G , TugwellP, SheaBet al.: Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rev.23, 529–539(2002).
   PubMed Web of Science ®Google Scholar
• Torgerson DJ , Bell-SyerSE: Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.JAMA285, 2891–2897(2001).
   PubMed Web of Science ®Google Scholar
• Greenspan SL , EmkeyRD, BoneHGet al.: Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.137, 875–883(2002).
   PubMed Web of Science ®Google Scholar
• Greenspan SL , ResnickNM, ParkerRA: Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.JAMA289, 2525–2533(2003).
   PubMed Web of Science ®Google Scholar
• Kendler DL : Strontium ranelate – data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action.Curr. Osteoporos. Rep.4, 34–39(2006).
   PubMedGoogle Scholar
• Meunier PJ , RouxC, SeemanEet al.: The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468(2004).
   PubMed Web of Science ®Google Scholar
• Reginster JY , SeemanE, De Vernejoul MC et al.: Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–22(2005).
   PubMed Web of Science ®Google Scholar
• Neer RM , ArnaudCD, ZanchettaJRet al.: Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med.344, 1434–1441(2001).
   PubMed Web of Science ®Google Scholar
• Saag KG , ShaneE, BoonenSet al.: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med.357, 2028–2039(2007).
   PubMed Web of Science ®Google Scholar
• Canalis E , GiustinaA, BilezikianJP: Mechanisms of anabolic therapies for osteoporosis.N. Engl. J. Med.357, 905–916(2007).
   PubMed Web of Science ®Google Scholar
• Greenspan SL , BoneHG, EttingerMPet al.: Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med.146, 326–339(2007).
   PubMed Web of Science ®Google Scholar
• Carey JJ : What is a ‘failure’ of bisphosphonate therapy for osteoporosis?Cleve. Clin. J. Med.72, 1033–1039(2005).
   PubMed Web of Science ®Google Scholar
• Deal C , OmizoM, SchwartzENet al.: Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res.20, 1905–1911(2005).
   PubMed Web of Science ®Google Scholar
• Khosla S : Parathyroid hormone plus alendronate – a combination that does not add up.N. Engl. J. Med.349, 1277–1279(2003).
   PubMed Web of Science ®Google Scholar
• Martino S , CauleyJA, Barrett-ConnorEet al.: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J. Natl Cancer Inst.96, 1751–1761(2004).
   PubMed Web of Science ®Google Scholar
• Amin S : Male osteoporosis: epidemiology and pathophysiology.Curr. Osteoporos. Rep.1, 71–77(2003).
   PubMedGoogle Scholar
• Orwoll ES , ScheeleWH, PaulSet al.: The effect of teriparatide (human parathyroid hormone [1–34]) therapy on bone density in men with osteoporosis. J. Bone Miner. Res.18, 9–17(2003).
   PubMed Web of Science ®Google Scholar
• Behre HM , KlieschS, LeifkeE, LinkTM, NieschlagE: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.J. Clin. Endocrinol. Metab.82, 2386–2390(1997).
   PubMed Web of Science ®Google Scholar
• Smith MR , FallonMA, LeeH, Finkelstein JS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J. Clin. Endocrinol. Metab.89, 3841–3846(2004).
   PubMed Web of Science ®Google Scholar
• Finkelstein JS , HayesA, HunzelmanJL, WylandJJ, LeeH, NeerRM: The effects of parathyroid hormone, alendronate, or both in men with osteoporosis.N. Engl. J. Med.349, 1216–1226(2003).
   PubMed Web of Science ®Google Scholar
• Sambrook PN , RodriguezJP, WasnichRDet al.: Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos. Int.15, 483–488(2004).
   PubMed Web of Science ®Google Scholar
• van den Boogaard CH , Breekveldt-PostmaNS, BorggreveSE, GoettschWG, HeringsRM: Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study.Curr. Med. Res. Opin.22, 1757–1764(2006).
   PubMed Web of Science ®Google Scholar
• Karnik AA , von Feldt JM: Osteoporosis. In: Lippincott‘s Primary Care Orthopaedics. Lotke PA, Abboud JA, Ende J (Eds). Lippincott Williams & Wilkins, Baltimore MD, USA, 343–351(2008).
   Google Scholar

Websites

• World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAX–WHO Fracture Risk Assessment Tool. (Accessed June18, 2008) www.shef.ac.uk/FRAX/index.htm
   Google Scholar
• National Osteoporosis Foundation. Clinician‘s Guide to Prevention and Treatment of Osteoporosis. (Accessed June18, 2008) www.nof.org/professionals/NOF_Clinicians_Guide.pdf
   Google Scholar